FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2470260050> ?p ?o ?g. }

• W2470260050 endingPage "343" @default.
• W2470260050 startingPage "343" @default.
• W2470260050 abstract "343 Background: There is no validated option beyond gemcitabine plus platinum standard first-line combination for advanced cholangiocarcinoma (CK). Second-line 5FU-based chemotherapy yields a median progression-free survival (PFS) and overall survival (OS) of 3 and 6-7 months, respectively. Intrahepatic CK subtypes overexpress VEGF, providing a rationale for testing sunitinib as second-line treatment in patients (pts) with advanced intrahepatic CK. Methods: A multicenter phase 2 study was designed for pts with locally advanced or metastatic intrahepatic CK after failure of first-line gemcitabine-based chemotherapy. Sunitinib was given at the dose of 37.5 mg/day continuously until disease progression or limiting toxicity. Pts were required to be ECOG PS 0-1 and with adequate liver function (alkaline phosphatase and transaminases < 5ULN, bilirubin <1.5ULN). Main objective was to exceed a median OS of 6.3 months. Secondary endpoints were PFS, response (RECIST 1.1 & Choi criteria), safety, pharmacokinetics (PK) and biomarker analysis (VEGFA, VEGFC, sKIT, HGF, SDF1, and osteopontin). Results: 53 pts were enrolled, with 34 pts evaluable for intermediate safety and efficacy analysis. Median age was 62 years (range 36–80), with 19 females/15 males. ECOG PS was 0/1 in 23/11 pts. Sixteen pts had prior surgical resection and 8 pts received adjuvant chemotherapy. Five pts (15%) had partial responses and 24 stable diseases (71%) by RECIST (disease control rate 85%). Ten pts had disease control > 6 months (range 6-14 months). With a median follow-up of 15.4 months, median OS was 9.6 months [95%CI: 5.8-13.1]. Median PFS was 5.2 months. Frequent adverse events were grade (Gr) 1-2 asthenia (80% of pts), mucositis (80%), diarrhea (60%), and hand-foot syndrome (43%). Gr 3/4 asymptomatic hematological toxicity occurred in 25% of pts (neutropenia n=8, thrombocytopenia n=7), Gr 3 hypertension was observed in 7 pts, and Gr 3 asthenia in 4 pts. Updated PK and biomarker analysis will be presented at the meeting. Conclusions: Second line sunitinib is well tolerated and shows promising activity with a 9.6-month OS in pts with advanced intrahepatic CK. Clinical trial information: NCT01718327." @default.
• W2470260050 created "2016-07-22" @default.
• W2470260050 creator A5002652584 @default.
• W2470260050 creator A5002864173 @default.
• W2470260050 creator A5008077511 @default.
• W2470260050 creator A5008863246 @default.
• W2470260050 creator A5009280778 @default.
• W2470260050 creator A5013525685 @default.
• W2470260050 creator A5013952219 @default.
• W2470260050 creator A5017132355 @default.
• W2470260050 creator A5031623063 @default.
• W2470260050 creator A5035411007 @default.
• W2470260050 creator A5043245662 @default.
• W2470260050 creator A5063395534 @default.
• W2470260050 creator A5071129301 @default.
• W2470260050 creator A5073655851 @default.
• W2470260050 creator A5080960118 @default.
• W2470260050 creator A5083719549 @default.
• W2470260050 creator A5086885079 @default.
• W2470260050 date "2015-01-20" @default.
• W2470260050 modified "2023-10-18" @default.
• W2470260050 title "Sunitinib as second-line treatment in patients with advanced intrahepatic cholangiocarcinoma (SUN-CK phase II trial): Safety, efficacy, and updated translational results." @default.
• W2470260050 doi "https://doi.org/10.1200/jco.2015.33.3_suppl.343" @default.
• W2470260050 hasPublicationYear "2015" @default.
• W2470260050 type Work @default.
• W2470260050 sameAs 2470260050 @default.
• W2470260050 citedByCount "13" @default.
• W2470260050 countsByYear W24702600502015 @default.
• W2470260050 countsByYear W24702600502017 @default.
• W2470260050 countsByYear W24702600502018 @default.
• W2470260050 countsByYear W24702600502019 @default.
• W2470260050 countsByYear W24702600502020 @default.
• W2470260050 countsByYear W24702600502021 @default.
• W2470260050 crossrefType "journal-article" @default.
• W2470260050 hasAuthorship W2470260050A5002652584 @default.
• W2470260050 hasAuthorship W2470260050A5002864173 @default.
• W2470260050 hasAuthorship W2470260050A5008077511 @default.
• W2470260050 hasAuthorship W2470260050A5008863246 @default.
• W2470260050 hasAuthorship W2470260050A5009280778 @default.
• W2470260050 hasAuthorship W2470260050A5013525685 @default.
• W2470260050 hasAuthorship W2470260050A5013952219 @default.
• W2470260050 hasAuthorship W2470260050A5017132355 @default.
• W2470260050 hasAuthorship W2470260050A5031623063 @default.
• W2470260050 hasAuthorship W2470260050A5035411007 @default.
• W2470260050 hasAuthorship W2470260050A5043245662 @default.
• W2470260050 hasAuthorship W2470260050A5063395534 @default.
• W2470260050 hasAuthorship W2470260050A5071129301 @default.
• W2470260050 hasAuthorship W2470260050A5073655851 @default.
• W2470260050 hasAuthorship W2470260050A5080960118 @default.
• W2470260050 hasAuthorship W2470260050A5083719549 @default.
• W2470260050 hasAuthorship W2470260050A5086885079 @default.
• W2470260050 hasConcept C121608353 @default.
• W2470260050 hasConcept C126322002 @default.
• W2470260050 hasConcept C141071460 @default.
• W2470260050 hasConcept C143998085 @default.
• W2470260050 hasConcept C203092338 @default.
• W2470260050 hasConcept C2776694085 @default.
• W2470260050 hasConcept C2778336483 @default.
• W2470260050 hasConcept C2778822529 @default.
• W2470260050 hasConcept C2779490328 @default.
• W2470260050 hasConcept C2779984678 @default.
• W2470260050 hasConcept C2780258809 @default.
• W2470260050 hasConcept C2780739268 @default.
• W2470260050 hasConcept C2909135397 @default.
• W2470260050 hasConcept C31760486 @default.
• W2470260050 hasConcept C535046627 @default.
• W2470260050 hasConcept C71924100 @default.
• W2470260050 hasConcept C90924648 @default.
• W2470260050 hasConceptScore W2470260050C121608353 @default.
• W2470260050 hasConceptScore W2470260050C126322002 @default.
• W2470260050 hasConceptScore W2470260050C141071460 @default.
• W2470260050 hasConceptScore W2470260050C143998085 @default.
• W2470260050 hasConceptScore W2470260050C203092338 @default.
• W2470260050 hasConceptScore W2470260050C2776694085 @default.
• W2470260050 hasConceptScore W2470260050C2778336483 @default.
• W2470260050 hasConceptScore W2470260050C2778822529 @default.
• W2470260050 hasConceptScore W2470260050C2779490328 @default.
• W2470260050 hasConceptScore W2470260050C2779984678 @default.
• W2470260050 hasConceptScore W2470260050C2780258809 @default.
• W2470260050 hasConceptScore W2470260050C2780739268 @default.
• W2470260050 hasConceptScore W2470260050C2909135397 @default.
• W2470260050 hasConceptScore W2470260050C31760486 @default.
• W2470260050 hasConceptScore W2470260050C535046627 @default.
• W2470260050 hasConceptScore W2470260050C71924100 @default.
• W2470260050 hasConceptScore W2470260050C90924648 @default.
• W2470260050 hasIssue "3_suppl" @default.
• W2470260050 hasLocation W24702600501 @default.
• W2470260050 hasOpenAccess W2470260050 @default.
• W2470260050 hasPrimaryLocation W24702600501 @default.
• W2470260050 hasRelatedWork W2248788750 @default.
• W2470260050 hasRelatedWork W2269843436 @default.
• W2470260050 hasRelatedWork W2588389046 @default.
• W2470260050 hasRelatedWork W2589786235 @default.
• W2470260050 hasRelatedWork W2596133298 @default.
• W2470260050 hasRelatedWork W2599443269 @default.
• W2470260050 hasRelatedWork W2620160838 @default.
• W2470260050 hasRelatedWork W2889701300 @default.
• W2470260050 hasRelatedWork W3000437623 @default.

• next